

PRODUCT INFORMATION



UTL-5g

Item No. 42242

CAS Registry No.: 646530-37-2

Formal Name: N-(2,4-dichlorophenyl)-5-methyl-3-isoxazolecarboxamide

MF: $C_{11}H_8Cl_2N_2O_2$


FW: 271.1

Purity: $\geq 98\%$

Supplied as: A solid

Storage: -20°C

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

UTL-5g is supplied as a solid. A stock solution may be made by dissolving the UTL-5g in the solvent of choice, which should be purged with an inert gas. UTL-5g is sparingly soluble (1-10 mg/ml) in DMSO and slightly soluble (0.1-1 mg/ml) in ethanol.

Description

UTL-5g is a chemo- and radioprotective agent.¹⁻³ It reduces LPS-induced transcriptional activity mediated by a variety of immune-related transcription factors, including STAT1, STAT2, STAT3, and SMAD2-4 but not NF- κ B in RAW 264.7 macrophages.¹ It also reduces hyperphosphorylation of proteins involved in the G₂/M phase transition, phagocytosis, and actin remodeling. It reduces radiation-induced increases in liver TNF- α levels in mice when administered at doses of 30 and 60 mg/kg and is protective against liver radiation-induced hepatotoxicity in mice at 60 mg/kg.² Oral administration of UTL-5g (60 mg/kg) increases the survival rate in a mouse model of acute cisplatin (Item No. 13119) toxicity.³

References

1. Carruthers, N.J., Stemmer, P.M., Chen, B., *et al.* Phosphoproteome and transcription factor activity profiling identify actions of the anti-inflammatory agent UTL-5g in LPS stimulated RAW 264.7 cells including disrupting actin remodeling and STAT-3 activation. *Eur. J. Pharmacol.* **811**, 66-73 (2017).
2. Shaw, J., Zhang, J., Zhang, M., *et al.* Pretreatment with a small-molecule tumor necrosis factor- α (TNF- α) inhibitor, UTL-5g, reduced radiation-induced acute liver toxicity in mice. *Am. J. Biomed. Sci.* **4**(2), 123-131 (2011).
3. Shaw, J., Media, J., Chen, B., *et al.* The small-molecule TNF- α inhibitor, UTL-5g, delays deaths and increases survival rates for mice treated with high doses of cisplatin. *Cancer Chemother. Pharmacol.* **72**(3), 703-707 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/18/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM